Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.18 USD | +1.73% | +15.42% | 0.00% |
Apr. 22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
Apr. 22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 245M | |
+9.45% | 114B | |
+13.40% | 107B | |
-10.86% | 22.22B | |
-2.07% | 21.28B | |
-4.59% | 18.8B | |
-5.35% | 17.51B | |
-39.93% | 17.17B | |
+8.84% | 14.14B | |
+34.57% | 12.2B |
- Stock Market
- Equities
- BOLD Stock
- News Boundless Bio, Inc.
- Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target